Therapy Directory

Olaparib clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Olaparib as a study intervention. Browse Olaparib recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 8:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

226

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Ovarian Cancer
Interventions: Olaparib, Ceralasertib, Placebo to match olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 22
States / cities: Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more

Conditions: Ovarian Cancer, Breast Cancer
Interventions: BKM120 and Olaparib, BYL719 and Olaparib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Houston, Texas

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: Durvalumab, Olaparib; Biological · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions: Olaparib, Radical Prostatectomy; Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Paclitaxel,, Bevacizumab, Cisplatin, Olaparib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • Harrison, New York + 2 more

Conditions: Ovarian Cancer, Breast Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer
Interventions: Carboplatin, Olaparib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Neoplasms
Interventions: AZD2281, Liposomal Doxorubicin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • Boca Raton, Florida + 3 more

Conditions: Refractory Solid Tumours, Relapsed Small Cell Lung Cancer (SCLC)
Interventions: AZD1775, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Denver, Colorado • Sarasota, Florida • New York, New York + 2 more

Conditions: Breast Cancer, Ovarian Cancer
Interventions: AZ2281 + Carboplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Olaparib, Cetuximab, Radiation Therapy; Drug · Radiation
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Breast Cancer
Interventions: Olaparib, Carboplatin, Anthracycline, Cyclophosphamide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: New York, New York • Stony Brook, New York

Conditions: Ovarian Neoplasm
Interventions: KU-0059436 (AZD2281)(PARP inhibitor); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more

About this Olaparib clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Olaparib as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Olaparib.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Olaparib clinical trials

Filter and sort this therapy

Live official records

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women s Cancers

Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History

A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

About this Olaparib clinical trials directory page